摘要
目的初步探讨粒细胞集落刺激因子(G-CSF)动员自体骨髓干细胞治疗急性缺血性脑卒中的有效性及安全性。方法将25例急性缺血性脑卒中患者随机分为G-CSF治疗组和对照组。G-CSF治疗组12例,接受G-CSF(5μg/kg皮下注射,1次/d连续7d)和常规治疗;对照组13例,接受常规治疗;观察治疗前及治疗后1个月或出院时神经功能缺损程度,并随访6个月时临床神经功能及日常生活活动能力。结果治疗1个月时或出院时G-CSF治疗组神经功能缺损评分较对照组略有改善,但差异无显著意义(t=0.842,P>0.05),但随访6个月时G-CSF治疗组的疗效明显优于对照组(Uc=1.801,P<0.05),日常生活活动能力的恢复亦优于对照组(t=2.587,P<0.05),G-CSF治疗组未出现严重不良反应。结论G-CSF动员自体骨髓干细胞治疗急性缺血性脑卒中有效、安全。
Objective To test the validity and security of granulicyte colony-stimulating factor(G-CSF) mobilized autogeneic bone marrow stem cells in treating acute ischemic stroke. Methods 90 patients with acute ischemic cerebral stroke were divided randomly into the G-CSF trentment group and the controlled group. Patients in G-CSF treatment group were 12, G-CSF was applied 1 time a day for 7 days per 5μg/kg with hypodermic injection. To observe MESSS before the treatment and after the treatment at one month or discharge, and follow-up to 6 months for activity of daily life (ADL) and functional recovery. Results After the treatment at one month or discharge the MESSS in G-CSF treatment group and the controlled group had no significant difference(t=0.842, P > 0.05 ). Follow-up to 6 months, the G-CSF treatment group was much better than the controlled group in therapeufic effect(U_ c =1.801, P < 0.05 ), ADL was much better than the controlled group as well(t=2.587, P < 0.05 ).No major adverse events were observed in the treatment group. Conclusions G-CSF mobilized autogeneic bone marrow stem cells treat acute ischemic stroke was effective and safe,it can enlarge sample size to evaluate therapeufic effecf more reliablely.
出处
《卒中与神经疾病》
2005年第3期161-163,共3页
Stroke and Nervous Diseases
基金
深圳市科委科研基金资助课题(课题号:200404061)
关键词
脑缺血
粒细胞集落刺激因子
Brain ischemia Granulocyte colony-stimulating factor
